LIPO Lipella Pharmaceuticals Inc.

Subscribe to $LIPO

Lipella Pharmaceuticals Inc.

Subscribe to $LIPO

$LIPO

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year: 2022

Exchange: NASDAQ

Recent Analyst Ratings for Lipella Pharmaceuticals Inc.

Date	Price Target	Rating	Analyst

See more ratings

Lipella Pharmaceuticals Inc. Press Releases

Fastest customizable press release news feed in the world

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today shar
2/11/25 5:46:44 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure. Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain,
2/6/25 6:00:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement
New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions. The private placements were successfully completed, subject to customary closing conditions. The proceeds from these offerings will support Lipella's continued advancement of its clinical pipeline and general corpor
1/10/25 1:24:38 PM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions
New York, NY, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is proud to announce a series of notable transactions completed in December 2024, further solidifying its reputation as a trusted partner for fast-growing companies across diverse industries. Spartan Capital facilitated a private placement valued at approximately $17 million for Burkhan World Investments. Headquartered in Washington, D.C., and Abu Dhabi, Burkhan blends strategic foresight with societal impact across sectors including telecom, energy, technology, and food security. Under the leadership of founder Shahal Khan, Burkhan continues to advance equity-based ec
12/31/24 11:55:42 AM ET
$EFSH
$LIPO
Professional Services
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement
New York, NY, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities LLC, a premier investment banking firm, is pleased to announce the successful completion of a private placement for Lipella Pharmaceuticals Inc.'s (NASDAQ:LIPO) Spartan Capital Securities, LLC acted as the sole placement agent in the private offer and sale of up to 6,000,000 of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, successfully raised $1,722,000 through this private placement. The private placement closed on December 16, 2024, as per schedule, subject to customary closing Conditions.The proceeds fro
12/18/24 2:28:31 PM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today announced the publication of a peer-reviewed paper in CUREUS. Titled "Rationale for the Use of Topical Calcineurin Inhibitors in the Management of Oral Lichen Planus and Mucosal Inflammatory Diseases," the paper focuses on non-steroid treatments for oral lichen planus (OLP), particularly topical calcineurin inhibitors (TCIs) such as tacrolimus. TCIs are non-steroidal medications used to treat inflammatory and autoimmune conditions by targeting the enzyme calcineurin, critical for T-cell
12/3/24 8:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all p
11/21/24 5:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024. This patent, titled "Delivery of Agents Using Metastable Liposomes," covers key technological innovations that enable the targeted delivery of therapeutic agents using liposome-based vehicles. The patent's claims cover Lipella's method of using metastable liposomes to deliver th
11/12/24 5:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) (the "Company," "our" or "us"), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company's certificate of incorporation with the Secretary of State of the State of Delaware. The Company expects that its common stock will begin trading on a split-adjusted basis when the market opens on November 8, 2024, under its current tra
11/1/24 4:30:00 PM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
PITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Spartan Capital Investor Conference that is being held on November 4, 2024, at the Pierre Hotel in New York. Event: Lipella Presentation - 2024 Spartan Capital Investor Conference Date: Monday, November 4th, 2024 Time: 9:25 am EST Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference. About Lipella PharmaceuticalsLipella is a clinical-s
10/29/24 8:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care

Lipella Pharmaceuticals Inc.

Recent Analyst Ratings for Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc.

Recent Analyst Ratings for Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. Press Releases

Fastest customizable press release news feed in the world

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement

Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

Lipella Pharmaceuticals Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

Lipella Pharmaceuticals Inc. SEC Filings

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13D/A filed by Lipella Pharmaceuticals Inc.

SEC Form 424B3 filed by Lipella Pharmaceuticals Inc.

SEC Form EFFECT filed by Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

SEC Form D filed by Lipella Pharmaceuticals Inc.

SEC Form S-3 filed by Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

Lipella Pharmaceuticals Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Officer Kaufman Jonathan H

SEC Form 4 filed by Officer Kaufman Jonathan H

SEC Form 4 filed by Officer Kaufman Jonathan H

Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

SEC Form 4 filed by Pruchnic Ryan

SEC Form 4 filed by Yoshimura Naoki

SEC Form 4 filed by Chancellor Michael B

SEC Form 4 filed by Birder Lori

Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

SEC Form 4 filed by Johnston Douglas

Lipella Pharmaceuticals Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)